PolyTherics is granted a further patent for its TheraPEG PEGylation technology
PolyTherics has successfully applied its TheraPEG™ technology to a range of proteins and peptides, including interferons, blood factors and a variety of antibody formats. The latter include antibody fragments (Fabs), single chain antibodies (scFv) and novel entities such as MacroGenics’ Dual-Affinity Re-Targeting molecules (DART™). Nuron Biotech Inc has recently announced an exclusive option and license agreement with PolyTherics to use TheraPEG™ to develop NU400, a long-acting version of its proprietary recombinant human interferon beta-1b, which could enter the clinic in 2012 for the treatment of multiple sclerosis.
John Burt, CEO of PolyTherics commented: “We are pleased that our TheraPEG™ patent estate has been further extended in the US with this second US patent, which strengthens our position in offering a solution for proteins and peptides in need of half-life extension. Licensees of PolyTherics’ TheraPEG™ technology will enjoy the benefit of the additional patent protection for their products developed using the TheraPEG™ technology”.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.